Investment Thesis
uniQure is a severely unprofitable pharmaceutical company burning $38.2M in operating cash quarterly with only $3.6M in revenue and 14-16 months of cash runway at current burn rate. The catastrophic 40.6% YoY revenue decline, negative operating margin of -1283.5%, and $53.5M net loss indicate failed commercialization of existing products and insufficient pipeline advancement to offset R&D burn.
Strengths
- Strong liquidity with 10.4x current ratio and $140M cash reserves
- Moderate leverage with 0.33x debt-to-equity ratio
- EPS improving year-over-year (-0.85 vs worse prior period) showing loss trajectory narrowing
Risks
- Acute cash runway risk: $38.2M quarterly burn implies 14-16 months until insolvency without capital raise
- Revenue collapsed 40.6% YoY suggesting commercialization failure, discontinued products, or failed partnerships
- Catastrophic profitability metrics: -1283.5% operating margin, -1502.9% net margin, negative ROE of -35.8%
- Negative free cash flow of -$38.4M indicates unsustainable operations requiring immediate strategic intervention
- Early-stage development profile (massive R&D burn) with no indication of near-term revenue inflection
Key Metrics to Watch
- Quarterly revenue trends and sequential burn rate sustainability
- Regulatory approvals, clinical trial milestones, and commercial product launches
- Cash balance depletion rate and capital raise announcements or debt restructuring
Financial Metrics
Revenue
3.6M
Net Income
-53.5M
EPS (Diluted)
$-0.85
Free Cash Flow
-38.4M
Total Assets
778.7M
Cash
140.0M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-1,283.5%
Net Margin
-1,502.9%
ROE
-35.8%
ROA
-6.9%
FCF Margin
-1,077.6%
Balance Sheet & Liquidity
Current Ratio
10.40x
Quick Ratio
10.27x
Debt/Equity
0.33x
Debt/Assets
80.8%
Interest Coverage
-2.84x
Long-term Debt
49.9M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-07T10:20:29.116144 |
Data as of: 2026-03-31 |
Powered by Claude AI